Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
17 Julio 2023 - 7:00AM
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that
it will host a conference call and live webcast on Tuesday, July
25, 2023 at 8:30 a.m. Eastern Time to report its second quarter
2023 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors &
Media section of the company’s website at www.kiniksa.com.
Individuals interested in participating in the call via telephone
may register here. Upon registration, all telephone participants
will receive a confirmation email detailing how to join the
conference call, including the dial-in number along with a unique
passcode and registrant ID that can be used to access the call. A
replay of the event will also be available on Kiniksa’s website
within approximately 48 hours after the event.
About KiniksaKiniksa is a biopharmaceutical
company focused on discovering, acquiring, developing, and
commercializing therapeutic medicines for patients suffering from
debilitating diseases with significant unmet medical need.
Kiniksa’s immune-modulating assets, ARCALYST, KPL-404, and
mavrilimumab, are based on strong biologic rationale or validated
mechanisms, target a spectrum of underserved cardiovascular and
autoimmune conditions, and offer the potential for differentiation.
For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
Every Second
Counts! ®Kiniksa Investor and
Media ContactRachel Frank(339)
970-9437rfrank@kiniksa.com |
|
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Gráfica de Acción Histórica
De May 2023 a May 2024